- March 9, 2020
Event LocationWhite Oak Campus: The Great Room
10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
- Organized By:
The Food and Drug Administration (FDA) is announcing the following public workshop entitled "Detecting Circulating Tumor DNA for Cancer Screening." The purpose of the workshop is to bring together experts from several disciplines and across multiple sectors to discuss the appropriate study designs needed to demonstrate the safety and effectiveness of cancer screening tests and to support claims of cancer screening. The goal is to discuss the clinical, scientific, and regulatory challenges associated with the development of Circulating Tumor DNA (ctDNA) based cancer screening tests.
All cells have a finite lifetime. After cell death, many types of cells release their interior contents into the bloodstream for subsequent degradation, including their DNA. This process also applies to many types of cancer cells, which carry unique DNA variants not present in normal cells. Recent advances in the technology to isolate ctDNA from blood samples, coupled with advances in the ability to detect these unique cancer-specific variants, have fueled the development of cancer screening tests using ctDNA in asymptomatic subjects. At this time, FDA would like to discuss the optimal regulatory approach for this developing technology given that there are several clinical and scientific challenges associated with these screening tests. Such challenges include the ideal clinical study design to determine the requisite level of sensitivity and specificity for these tests and the data needed to assess whether the benefits of such tests outweigh the risks.
DATE, TIME and LOCATION
This public workshop will be held March 9, 2020, from 9:00 a.m. to 5:00 p.m. (EST) at the following location:
FDA White Oak Campus
10903 New Hampshire Avenue
Bldg. 31, Room 1503 (the Great Room)
Silver Spring, MD, 20993
FDA Campus Information, (e.g., local airports, directions, local hotels, etc.)
The following public meeting draft Agenda is preliminary and subject to change. More information will be made available as presenters are confirmed.
|8:00 – 9:00||Security Screening and Registration|
|9:00 – 9:15||
Welcome and Introduction
|9:15 – 10:45||
Session 1: State of the Science: Technical Considerations and Translation of Results into Clinical Actionability
|10:45 – 10:55||Break|
|10:55 – 12:25||
Session 2: Clinical Validation for Single Cancer Screening Tests vs. Multi-Cancer Tests
|12:25 – 1:35||Lunch Break|
|1:35 – 2:20||
Session 3: Public Comment
|2:20 – 3:50||
Session 4: Clinical Study Design Considerations
|3:50 – 4:00||
Online registration is closed. Onsite registraton will be available beginning at 8:00 am the morning of the workshop.
There is no fee to register for the Workshop. Early registration is recommended because seating is limited. Registration will be on a first-come, first-served basis.
If you require special accommodations due to a disability, or need additional information regarding registration, please contact Susan Monahan, Office of Communication and Education, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg. 32 - Room 5255, Silver Spring, MD 20993, 301-796-5661, Susan.Monahan@fda.hhs.gov.
Please submit your comments regarding the workshop to https://www.regulations.gov, Docket No. FDA-2020-N-0708 by April 6, 2020.
Please refer to the Instructions for submitting comments to the docket to ensure that your feedback is received.
The meeting transcript will be posted to the Docket as soon as it is available, and accessible at http://www.regulations.gov.
For questions regarding workshop content please contact:
Abdelrahmman (Abde) Abukhdeir
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Ave.
Bldg. 66, Rm. 3302
Silver Spring, MD 20993
|Instructions for Submitting Comments - DNA Cancer Screenings Workshop||pdf (25.88 KB)|
|Transcript for DNA CANCER SCREENING||pdf (831.89 KB)|